首页> 美国卫生研究院文献>Source Code for Biology and Medicine >Molecular-docking study of malaria drug target enzyme transketolase in Plasmodium falciparum 3D7 portends the novel approach to its treatment
【2h】

Molecular-docking study of malaria drug target enzyme transketolase in Plasmodium falciparum 3D7 portends the novel approach to its treatment

机译:恶性疟原虫3D7中疟疾药物靶酶转酮酶的分子对接研究预示了其新的治疗方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMalaria has been a major life threatening mosquito borne disease from long since. Unavailability of any effective vaccine and recent emergence of multi drug resistant strains of malaria pathogen Plasmodium falciparum continues to cause persistent deaths in the tropical and sub-tropical region. As a result, demands for new targets for more effective anti-malarial drugs are escalating. Transketolase is an enzyme of the pentose phosphate pathway; a novel pathway which is involved in energy generation and nucleic acid synthesis. Moreover, significant difference in homology between Plasmodium falciparum transketolase (Pftk) and human (Homo sapiens) transketolase makes it a suitable candidate for drug therapy. Our present study is aimed to predict the 3D structure of Plasmodium falciparum transketolase and design an inhibitor against it.
机译:背景疟疾自长期以来一直是威胁生命的主要蚊媒疾病。无法获得任何有效的疫苗以及疟疾病原体恶性疟原虫的多药耐药菌株的近期出现,继续在热带和亚热带地区造成持续死亡。结果,对于更有效的抗疟疾药物的新目标的需求正在增加。转酮醇酶是戊糖磷酸途径的酶。与能量产生和核酸合成有关的新途径。而且,恶性疟原虫转酮醇酶(Pftk)和人(智人)转酮醇酶之间的同源性显着不同,使其成为药物治疗的合适候选者。我们目前的研究旨在预测恶性疟原虫转酮醇酶的3D结构并设计针对其的抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号